A Randomized, double-blind, dose ranging clinical trial of intravenous FDY-5301 in acute STEMI patients undergoing primary PCI
David Adlam(University College London), Keith M. Channon(University of Oxford), Joseph B. Selvanayagam(Flinders Medical Centre), Lori S. Siegel(Faraday Technology (United States)), Michael A. Insko(Faraday Technology (United States)), John Irving(Ninewells Hospital), János Tomcsányi, Azfar Zaman(Royal Stoke University Hospital), Maciej Zarębiński, Simon Tulloch(Faraday Technology (United States)), Gergely Nagy(Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktató Kórház), Cheerag Shirodaria(Oxford University Hospitals NHS Trust), István Édes(University of Debrecen), Piotr Musiałek(Jagiellonian University), Joanna Szachniewicz, Keith G. Oldroyd(Biosensores (Spain)), Paweł Ptaszyński(Medical University of Lodz), Leong L. Ng(University of Leicester), Shahzad Munir(New Cross Hospital), Mark J. Roth(National Cancer Institute), Mario J. García(Cleveland Clinic), Andrew Sharp(University Hospital of Wales), Pauline A. Quinn(University of Leicester), Neal Uren(Edinburgh Royal Infirmary), Géza Lupkovics(St. Raphael's Hospital), Hussain Contractor(National Health Service), Ben Haber(Faraday Technology (United States)), Stephen Hill(Faraday Technology (United States)), Róbert Gábor Kiss
Cited by 16
Related Papers
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
|New England Journal of Medicine|2015|2k
Preeclampsia and Future Cardiovascular Health
|Circulation Cardiovascular Quality and Outcomes|2017|1.1k
Randomized Trial of Preventive Angioplasty in Myocardial Infarction
|New England Journal of Medicine|2013|1k